Access Review Committee
The Access Review Committee (ARC) provides an independent examination of requests for data access, with regards to the acceptable uses of the Genomics England dataset. The acceptable uses are outlined in REC approved 100,000 Genomes Project Protocol and the Data Access and Acceptable Uses Policy. The ARC will decide to approve, decline, or amend requests for access to data. External expertise may be called upon to assist the decision-making process, where appropriate.
Up to four places are reserved for the representatives of the Participant Panel and they contribute and vote as any other member of the ARC. The individual Participant Panel representatives are free to rotate attendance at the ARC meetings according to their availability; at least one Participant Panel Representative must be in attendance for an ARC meeting to take place.
Professor Jonathan Knowles
In 2010, Professor Knowles was awarded the Scrip Lifetime Achievement Award for his long academic and commercial career distinguished by his passion for personalized medicine.
Jonathan Knowles holds a visiting chair at the University of Oxford, held a distinguished professorship in personalized health care at the Finnish Institute for Molecular Medicine at the University of Helsinki and is a Professor Emeritus at Ecole Polytechnique Fédérale de Lausanne in Switzerland. In addition, he is a Trustee of CRUK, a member of the European Molecular Biology Organization and a William Pitt Fellow of Pembroke College Cambridge. He serves on a number of academic and biotech boards and is currently Chairman of the board of Adappimunne Ltd and Immunocore Ltd.
Professor Stephen Holgate
Stephen Holgate is MRC Professor of Immuno-pharmacology at the University of Southampton. He studied medicine at Charing Cross and after training in respiratory medicine he undertook a two-year Fellowship at Harvard Medical School. On returning to Southampton in 1980, he pursued a research career on the mechanisms of asthma and allergy involving a wide range of different approaches.
Most recently, Stephen was chair of Main Panel A of the Research Excellence Framework, 2014. Currently, he chairs the NC3Rs Board, the Hazardous Substances Advisory Committee (Defra) and the European Respiratory Society Science Council. He also chairs the MRC Translational Group responsible for pulling through discovery science into patient benefit and is a member of the MRC Strategy Board and the NERC Science and Innovation Strategy Board.
Stephen has been appointed to the European Commission’s Scientific Panel for Health that will help set the research agenda for ‘Horizon 2020’. In 2011, he was appointed CBE for services to clinical science.
Alastair Kent OBE
Alastair Kent is the Director of Genetic Alliance UK – the national charity of over 180 patient organisations, supporting all those affected by genetic conditions. Genetic Alliance UK’s mission is to promote the development of the scientific understanding of genetics and the part that genetic factors play in health and disease, and to see the speedy transfer of this new knowledge into improved services and support for patients.
Alastair is also the Chair of Rare Disease UK (RDUK) the national alliance for people with rare diseases and all who support them. RDUK has over 1,500 members including over 250 patient organisations, health professionals, researchers, the pharmaceutical industry and individual patients and families.
Professor Parveen Kumar
Parveen Kumar is Professor of Medicine and Education at Barts and the London, Queen Mary University of London. She qualified in medicine at St Bartholomew’s Hospital Medical College after completing an intercalated BSc degree; her research was in small bowel disorders, particularly coeliac disease.
Kumar was appointed as a Non-Executive Director of the National Institute of Clinical Excellence (NICE) at its inception in 1999 and resigned this post in 2002 when she was appointed as the Chairman of the Medicines Commission UK. She has also served as a Non-Executive Director on an acute hospital Trust board. She chaired the Bupa Foundation for research for 3 years. She has been President of the British Medical Association, President of the Royal Society of Medicine and vice president of the Royal College of Physicians. She was awarded CBE for services to Medicine.
Professor Debbie Lawlor
Debbie Lawlor is Professor of Epidemiology and Deputy Director of the MRC Integrative Epidemiology Unit at the University of Bristol . Her main areas of expertise are in the life course and genetic epidemiology of women’s reproductive health, perinatal health and their relationship to cardiometabolic health. She also contributes to methodological research, particularly developing methods for improving causal inference with observational data. She has a medical background, two MSc (one in Public Health and one in Statistics) and a PhD in epidemiology.
Richard Stephens is a survivor of two cancers and a heart emergency. He has participated in four clinical trials and six other research studies, and currently serves on two trial management groups. His professional career has included work in education and local government.
As a patient advocate and representative in health and medical research, his principal role is as NCRI’s consumer lead. He chairs NCRI’s Consumer Forum and has sat on on several other national and regional committees and bodies, including CRUK’s CTAAC, NCC-C’s Management Board, NETS CC’s PPI SG, and HTA and RfPB funding committees.
Richard is joint Editor-In-Chief of BioMed Central’s new online open access Journal of Research Involvement and Engagement. He has co-authored conference abstracts and posters, two published academic papers, and 2012’s Action On Access, an influential consumer-led report recommending organisational and cultural changes to encourage and support more patients to participate in research.
He is also co-chair of the advisory committee to NIHR’s new Dissemination Centre, is a patient representative with Genomics England and the MRC CTU, and leads the innovative Patient Panel working with AstraZeneca.